Answers are grounded in this paper and cite their sources.
Psoriasis is a chronic, immune-mediated inflammatory skin disorder characterized by erythematous papules, silvery micaceous scales, and significant skin barrier dysfunction. While conventional therapies and standard emollients are widely utilized, they present critical limitations, including water-based formulations temporarily increasing transepidermal water loss (TEWL) and pure occlusives failing to significantly elevate stratum corneum hydration. Furthermore, systemic and biologic treatments are often restricted by high costs, adverse effects, and disease relapse. Addressing the absence of a unified topical system capable of simultaneously mitigating plaque inflammation and restoring epidermal integrity, the development of a Moringa oleifera-colloidal oatmeal emulgel presents a promising dual-action approach. By synergizing the anti-inflammatory and antioxidant phytoconstituents of Moringa oleifera with the barrier-restorative and humectant properties of colloidal oatmeal, this novel botanical emulgel overcomes conventional therapeutic drawbacks. Future perspectives point toward standardizing phytochemical constituents, optimizing transdermal delivery systems, and validating long-term safety and efficacy through rigorous clinical trials.
No takes yet. Share an insight, caveat, or question.
Payal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: